Purple Biotech (PPBT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Purple Biotech has announced encouraging interim results from their Phase 2 study of CM24 for pancreatic cancer, showing improved survival and response rates, and identified potential predictive biomarkers. The data, presented at the ASCO Annual Meeting, supports the expansion of CM24 clinical programs into biomarker-driven studies. With recent financing, the company has extended its cash runway into Q3 2025, anticipating further data and discussions with the FDA regarding pivotal studies.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.